Symbols / PFE $27.30 +0.52%
PFE Chart
About
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Gen | Market Cap | 155.24B |
| Enterprise Value | 209.59B | Income | 7.75B | Sales | 62.58B |
| Book/sh | 15.21 | Cash/sh | 2.39 | Dividend Yield | 6.30% |
| Payout | 126.47% | Employees | 75000 | IPO | — |
| P/E | 19.93 | Forward P/E | 9.65 | PEG | — |
| P/S | 2.48 | P/B | 1.79 | P/C | — |
| EV/EBITDA | 8.15 | EV/Sales | 3.35 | Quick Ratio | 0.80 |
| Current Ratio | 1.16 | Debt/Eq | 77.96 | LT Debt/Eq | — |
| EPS (ttm) | 1.37 | EPS next Y | 2.83 | EPS Growth | — |
| Revenue Growth | -1.20% | Earnings | 2026-04-28 | ROA | 5.68% |
| ROE | 8.89% | ROIC | — | Gross Margin | 75.81% |
| Oper. Margin | 23.95% | Profit Margin | 12.42% | Shs Outstand | 5.69B |
| Shs Float | 5.68B | Short Float | 2.51% | Short Ratio | 2.95 |
| Short Interest | — | 52W High | 27.94 | 52W Low | 20.92 |
| Beta | 0.41 | Avg Volume | 47.49M | Volume | 40.49M |
| Target Price | $28.43 | Recom | Buy | Prev Close | $27.16 |
| Price | $27.30 | Change | 0.52% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$28.43
Mean price target
2. Current target
$27.30
Latest analyst target
3. DCF / Fair value
$42.51
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$27.30
Low
$25.00
High
$35.46
Mean
$28.43
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-02 | up | Argus Research | Hold → Buy | $35 |
| 2026-02-25 | init | RBC Capital | — → Underperform | $25 |
| 2026-02-20 | init | Barclays | — → Underweight | $25 |
| 2026-02-04 | reit | Cantor Fitzgerald | Neutral → Neutral | $27 |
| 2026-01-27 | main | Cantor Fitzgerald | Neutral → Neutral | $27 |
| 2025-12-17 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $27 |
| 2025-12-15 | main | B of A Securities | Neutral → Neutral | $28 |
| 2025-12-12 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $28 |
| 2025-11-24 | main | Guggenheim | Buy → Buy | $35 |
| 2025-10-10 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $32 |
| 2025-10-03 | main | B of A Securities | Neutral → Neutral | $30 |
| 2025-08-06 | main | Citigroup | Neutral → Neutral | $26 |
| 2025-08-06 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $33 |
| 2025-08-06 | main | B of A Securities | Neutral → Neutral | $28 |
| 2025-04-30 | main | UBS | Neutral → Neutral | $25 |
| 2025-04-22 | init | Cantor Fitzgerald | — → Neutral | $24 |
| 2025-04-08 | main | UBS | Neutral → Neutral | $24 |
| 2025-04-08 | down | Goldman Sachs | Buy → Neutral | $25 |
| 2025-03-18 | reit | Guggenheim | Buy → Buy | — |
| 2025-03-12 | reit | Guggenheim | Buy → Buy | — |
News
RSS: Latest PFE news- 651,996 Shares in Pfizer Inc. $PFE Bought by Kepler Cheuvreux Suisse SA - MarketBeat Wed, 11 Mar 2026 11
- Pfizer Stock: Cheap For A Reason (NYSE:PFE) - Seeking Alpha Wed, 11 Mar 2026 08
- 1 Reason I'd Happily Buy Pfizer (PFE) Stock and Never Sell - The Motley Fool Mon, 02 Mar 2026 08
- Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026? - Yahoo Finance Mon, 02 Mar 2026 08
- Is There 25% Downside For Pfizer Stock? - Forbes Wed, 18 Feb 2026 08
- Why This Top 10% Stock Surged On Pfizer's Patent Shake-Up - Investor's Business Daily ue, 10 Mar 2026 21
- Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study - Reuters Mon, 09 Mar 2026 11
- Monthly Pfizer antibody improves atopic dermatitis, moves toward Phase 3 - Stock Titan Mon, 09 Mar 2026 10
- Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE) - The Globe and Mail Wed, 11 Mar 2026 17
- Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash? - The Motley Fool Fri, 20 Feb 2026 08
- Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance Fri, 06 Mar 2026 14
- Richard Bernstein Advisors LLC Has $1.33 Million Holdings in Pfizer Inc. $PFE - MarketBeat Wed, 11 Mar 2026 10
- 2 Top AI Healthcare Stocks to Buy and Hold - The Motley Fool Mon, 09 Mar 2026 16
- Does Pfizer (PFE) Offer Value After Post Pandemic Pipeline And Patent Concerns - Yahoo Finance Wed, 11 Mar 2026 06
- Pfizer's Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable? - Yahoo Finance Mon, 09 Mar 2026 18
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 21719 | — | — | Stock Award(Grant) at price 0.00 per share. | DAMICO JENNIFER B. | Officer | — | 2026-03-03 00:00:00 | D |
| 1 | 13383 | — | — | Stock Award(Grant) at price 0.00 per share. | BOSHOFF CHRISTOFFEL | Officer | — | 2026-02-25 00:00:00 | D |
| 2 | 56888 | 1923952 | — | Conversion of Exercise of derivative security at price 33.82 per share. | SAHNI PAYAL | Officer | — | 2026-02-25 00:00:00 | D |
| 3 | 37925 | 1282624 | — | Conversion of Exercise of derivative security at price 33.82 per share. | MCDERMOTT MICHAEL | Officer | — | 2026-02-25 00:00:00 | D |
| 4 | 17558 | 593812 | — | Conversion of Exercise of derivative security at price 33.82 per share. | DAMICO JENNIFER B. | Officer | — | 2026-02-25 00:00:00 | D |
| 5 | 491626 | 16626791 | — | Conversion of Exercise of derivative security at price 33.82 per share. | BOURLA ALBERT | Chief Executive Officer | — | 2026-02-25 00:00:00 | D |
| 6 | 56888 | 1923952 | — | Conversion of Exercise of derivative security at price 33.82 per share. | FONSECA LIDIA PH.D. | Officer | — | 2026-02-25 00:00:00 | D |
| 7 | 122907 | 4156715 | — | Conversion of Exercise of derivative security at price 33.82 per share. | LANKLER DOUGLAS M | Officer | — | 2026-02-25 00:00:00 | D |
| 8 | 5583 | — | — | Stock Award(Grant) at price 0.00 per share. | DAMICO JENNIFER B. | Officer | — | 2025-03-04 00:00:00 | D |
| 9 | 2500 | 64825 | — | Sale at price 25.93 per share. | DAMICO JENNIFER B. | Officer | — | 2025-03-04 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -1.88B | -939.96M | -872.13M | -293.86M |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.10 |
| NormalizedEBITDA | 25.75B | 22.60B | 13.71B | 44.09B |
| TotalUnusualItems | -8.96B | -4.48B | -4.15B | -3.06B |
| TotalUnusualItemsExcludingGoodwill | -8.96B | -4.48B | -4.15B | -3.06B |
| NetIncomeFromContinuingOperationNetMinorityInterest | 7.75B | 8.02B | 2.13B | 31.37B |
| ReconciledDepreciation | 6.59B | 7.01B | 6.29B | 5.06B |
| ReconciledCostOfRevenue | 14.35B | 16.12B | 23.40B | 32.89B |
| EBITDA | 16.78B | 18.13B | 9.56B | 41.03B |
| EBIT | 10.19B | 11.11B | 3.27B | 35.97B |
| NetInterestIncome | -2.07B | -2.55B | -585.00M | -987.00M |
| InterestExpense | 2.67B | 3.09B | 2.21B | 1.24B |
| InterestIncome | 603.00M | 545.00M | 1.62B | 251.00M |
| NormalizedIncome | 14.83B | 11.56B | 5.41B | 34.13B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 7.77B | 8.03B | 2.12B | 31.37B |
| TotalExpenses | 45.17B | 48.80B | 55.33B | 64.01B |
| DilutedAverageShares | 5.71B | 5.70B | 5.71B | 5.73B |
| BasicAverageShares | 5.68B | 5.66B | 5.64B | 5.61B |
| DilutedEPS | 1.36 | 1.41 | 0.37 | 5.47 |
| BasicEPS | 1.37 | 1.42 | 0.38 | 5.59 |
| DilutedNIAvailtoComStockholders | 7.77B | 8.03B | 2.12B | 31.37B |
| NetIncomeCommonStockholders | 7.77B | 8.03B | 2.12B | 31.37B |
| NetIncome | 7.77B | 8.03B | 2.12B | 31.37B |
| MinorityInterests | -41.00M | -31.00M | -39.00M | -35.00M |
| NetIncomeIncludingNoncontrollingInterests | 7.81B | 8.06B | 2.16B | 31.41B |
| NetIncomeDiscontinuousOperations | 25.00M | 11.00M | -15.00M | 6.00M |
| NetIncomeContinuousOperations | 7.79B | 8.05B | 2.17B | 31.40B |
| TaxProvision | -266.00M | -28.00M | -1.11B | 3.33B |
| PretaxIncome | 7.52B | 8.02B | 1.06B | 34.73B |
| OtherIncomeExpense | -7.82B | -4.26B | -2.58B | -1.45B |
| OtherNonOperatingIncomeExpenses | 1.14B | 113.00M | 1.07B | 1.18B |
| SpecialIncomeCharges | -9.16B | -5.76B | -6.22B | -2.10B |
| GainOnSaleOfPPE | 0.00 | 99.00M | ||
| GainOnSaleOfBusiness | 525.00M | 222.00M | ||
| OtherSpecialCharges | 2.67B | 567.00M | 474.00M | 230.00M |
| WriteOff | 432.00M | 227.00M | 52.00M | 53.00M |
| ImpairmentOfCapitalAssets | 4.94B | 3.29B | 3.02B | 421.00M |
| RestructuringAndMergernAcquisition | 1.55B | 2.42B | 2.94B | 1.45B |
| EarningsFromEquityInterest | 0.00 | 102.00M | 505.00M | 436.00M |
| GainOnSaleOfSecurity | 198.00M | 1.28B | 2.07B | -959.00M |
| NetNonOperatingInterestIncomeExpense | -2.07B | -2.55B | -585.00M | -987.00M |
| InterestExpenseNonOperating | 2.67B | 3.09B | 2.21B | 1.24B |
| InterestIncomeNonOperating | 603.00M | 545.00M | 1.62B | 251.00M |
| OperatingIncome | 17.41B | 14.83B | 4.22B | 37.16B |
| OperatingExpense | 29.11B | 30.95B | 30.38B | 29.67B |
| DepreciationAmortizationDepletionIncomeStatement | 4.87B | 5.29B | 4.73B | 3.61B |
| DepreciationAndAmortizationInIncomeStatement | 4.87B | 5.29B | 4.73B | 3.61B |
| Amortization | 4.87B | 5.29B | 4.73B | 3.61B |
| AmortizationOfIntangiblesIncomeStatement | 4.87B | 5.29B | 4.73B | 3.61B |
| ResearchAndDevelopment | 10.44B | 10.93B | 10.87B | 12.38B |
| SellingGeneralAndAdministration | 13.79B | 14.73B | 14.77B | 13.68B |
| GrossProfit | 46.51B | 45.78B | 34.60B | 66.83B |
| CostOfRevenue | 16.07B | 17.85B | 24.95B | 34.34B |
| TotalRevenue | 62.58B | 63.63B | 59.55B | 101.17B |
| OperatingRevenue | 62.58B | 63.63B | 59.55B | 101.17B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 3.94B | 3.93B | 3.92B | 3.90B |
| OrdinarySharesNumber | 5.69B | 5.67B | 5.65B | 5.62B |
| ShareIssued | 9.62B | 9.59B | 9.56B | 9.52B |
| NetDebt | 62.82B | 62.61B | 67.99B | 34.44B |
| TotalDebt | 63.96B | 63.65B | 70.84B | 34.86B |
| TangibleBookValue | -38.52B | -35.74B | -43.67B | 916.00M |
| InvestedCapital | 150.44B | 151.85B | 159.86B | 130.52B |
| WorkingCapital | 5.91B | 7.36B | -4.46B | 9.12B |
| NetTangibleAssets | -38.52B | -35.74B | -43.67B | 916.00M |
| CommonStockEquity | 86.48B | 88.20B | 89.01B | 95.66B |
| TotalCapitalization | 147.28B | 144.91B | 149.51B | 127.59B |
| TotalEquityGrossMinorityInterest | 86.78B | 88.50B | 89.29B | 95.92B |
| MinorityInterest | 299.00M | 294.00M | 274.00M | 256.00M |
| StockholdersEquity | 86.48B | 88.20B | 89.01B | 95.66B |
| OtherEquityInterest | 1.00M | 1.00M | ||
| GainsLossesNotAffectingRetainedEarnings | -8.07B | -7.84B | -7.96B | -8.30B |
| OtherEquityAdjustments | -321.00M | 57.00M | -217.00M | -412.00M |
| ForeignCurrencyTranslationAdjustments | -7.80B | -7.98B | -7.86B | -8.36B |
| MinimumPensionLiabilities | 75.00M | 191.00M | 128.00M | 248.00M |
| UnrealizedGainLoss | -28.00M | -106.00M | -9.00M | 220.00M |
| TreasuryStock | 115.02B | 114.76B | 114.49B | 113.97B |
| RetainedEarnings | 114.61B | 116.72B | 118.35B | 125.66B |
| AdditionalPaidInCapital | 94.47B | 93.60B | 92.63B | 91.80B |
| CapitalStock | 481.00M | 480.00M | 478.00M | 476.00M |
| CommonStock | 481.00M | 480.00M | 478.00M | 476.00M |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 121.39B | 124.90B | 137.21B | 101.29B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 84.40B | 81.90B | 89.42B | 59.15B |
| OtherNonCurrentLiabilities | 14.73B | 14.15B | 16.54B | 13.18B |
| DerivativeProductLiabilities | 834.00M | 701.00M | 1.04B | 959.00M |
| EmployeeBenefits | 2.04B | 2.12B | 2.17B | 2.25B |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 2.04B | 2.12B | 2.17B | 2.25B |
| TradeandOtherPayablesNonCurrent | 3.59B | 6.11B | 8.53B | 9.81B |
| NonCurrentDeferredLiabilities | 2.40B | 2.12B | 640.00M | 1.02B |
| NonCurrentDeferredTaxesLiabilities | 2.40B | 2.12B | 640.00M | 1.02B |
| LongTermDebtAndCapitalLeaseObligation | 60.81B | 56.70B | 60.50B | 31.93B |
| LongTermDebt | 60.81B | 56.70B | 60.50B | 31.93B |
| CurrentLiabilities | 36.98B | 42.99B | 47.79B | 42.14B |
| OtherCurrentLiabilities | 18.65B | 19.72B | 20.54B | 22.58B |
| CurrentDeferredLiabilities | 784.00M | 1.51B | 2.70B | 2.52B |
| CurrentDeferredRevenue | 784.00M | 1.51B | 2.70B | 2.52B |
| CurrentDebtAndCapitalLeaseObligation | 3.15B | 6.95B | 10.35B | 2.93B |
| CurrentDebt | 3.15B | 6.95B | 10.35B | 2.93B |
| OtherCurrentBorrowings | 3.15B | 4.49B | 2.38B | 2.93B |
| CommercialPaper | 0.00 | 2.45B | 7.96B | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.61B | 3.84B | 2.78B | 3.41B |
| PayablesAndAccruedExpenses | 10.79B | 10.98B | 11.43B | 10.70B |
| Payables | 10.79B | 10.98B | 11.43B | 10.70B |
| DividendsPayable | 2.44B | 2.44B | 2.37B | 2.30B |
| TotalTaxPayable | 3.10B | 2.91B | 2.35B | 1.59B |
| IncomeTaxPayable | 3.10B | 2.91B | 2.35B | 1.59B |
| AccountsPayable | 5.24B | 5.63B | 6.71B | 6.81B |
| TotalAssets | 208.16B | 213.40B | 226.50B | 197.21B |
| TotalNonCurrentAssets | 165.26B | 163.04B | 183.17B | 145.94B |
| OtherNonCurrentAssets | 9.63B | 9.82B | 12.47B | 13.16B |
| NonCurrentDeferredAssets | 9.70B | 8.66B | 3.71B | 6.69B |
| NonCurrentDeferredTaxesAssets | 9.70B | 8.66B | 3.71B | 6.69B |
| InvestmentsAndAdvances | 1.62B | 2.23B | 15.37B | 15.07B |
| OtherInvestments | 5.05B | |||
| InvestmentinFinancialAssets | 1.39B | 2.01B | 3.73B | 4.04B |
| HeldToMaturitySecurities | 48.00M | 45.00M | 47.00M | 48.00M |
| AvailableForSaleSecurities | 1.34B | 1.97B | 3.68B | 3.99B |
| LongTermEquityInvestment | 235.00M | 217.00M | 11.64B | 11.03B |
| GoodwillAndOtherIntangibleAssets | 124.99B | 123.94B | 132.68B | 94.75B |
| OtherIntangibleAssets | 53.73B | 55.41B | 64.90B | 43.37B |
| Goodwill | 71.26B | 68.53B | 67.78B | 51.38B |
| NetPPE | 19.32B | 18.39B | 18.94B | 16.27B |
| AccumulatedDepreciation | -17.39B | -16.48B | -16.05B | -15.17B |
| GrossPPE | 36.70B | 34.88B | 34.98B | 31.45B |
| ConstructionInProgress | 4.80B | 4.94B | 5.92B | 4.88B |
| OtherProperties | 1.00M | -1.00M | 1.00M | |
| MachineryFurnitureEquipment | 21.85B | 20.61B | 19.66B | 17.37B |
| BuildingsAndImprovements | 9.74B | 9.04B | 9.05B | 8.83B |
| LandAndImprovements | 299.00M | 291.00M | 353.00M | 368.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 42.90B | 50.36B | 43.33B | 51.26B |
| OtherCurrentAssets | 2.81B | 4.25B | 4.91B | 5.02B |
| Inventory | 10.65B | 10.85B | 10.19B | 8.98B |
| OtherInventories | -1.00M | -1.00M | ||
| FinishedGoods | 4.11B | 3.77B | 3.50B | 2.60B |
| WorkInProcess | 5.63B | 6.10B | 5.69B | 5.52B |
| RawMaterials | 907.00M | 976.00M | 1.01B | 859.00M |
| Receivables | 15.84B | 14.78B | 15.54B | 14.53B |
| TaxesReceivable | 3.97B | 3.31B | 3.98B | 3.58B |
| AccountsReceivable | 11.87B | 11.46B | 11.57B | 10.95B |
| AllowanceForDoubtfulAccountsReceivable | -427.00M | -438.00M | -470.00M | -449.00M |
| GrossAccountsReceivable | 12.30B | 11.90B | 12.04B | 11.40B |
| CashCashEquivalentsAndShortTermInvestments | 13.60B | 20.48B | 12.69B | 22.73B |
| OtherShortTermInvestments | 12.45B | 19.43B | 9.84B | 22.32B |
| CashAndCashEquivalents | 1.14B | 1.04B | 2.85B | 416.00M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 9.07B | 9.84B | 4.79B | 26.03B |
| RepurchaseOfCapitalStock | 0.00 | 0.00 | -2.00B | 0.00 |
| RepaymentOfDebt | -9.75B | -16.07B | -2.57B | -7.41B |
| IssuanceOfDebt | 9.68B | 8.91B | 38.52B | 3.89B |
| CapitalExpenditure | -2.63B | -2.91B | -3.91B | -3.24B |
| InterestPaidSupplementalData | 2.74B | 3.23B | 2.21B | 1.44B |
| IncomeTaxPaidSupplementalData | 4.69B | 3.60B | 3.15B | 7.87B |
| EndCashPosition | 1.20B | 1.11B | 2.92B | 468.00M |
| BeginningCashPosition | 1.11B | 2.92B | 468.00M | 1.98B |
| EffectOfExchangeRateChanges | 41.00M | -66.00M | -40.00M | -165.00M |
| ChangesInCash | 49.00M | -1.74B | 2.49B | -1.35B |
| FinancingCashFlow | -10.30B | -17.14B | 26.07B | -14.83B |
| CashFromDiscontinuedFinancingActivities | 0.00 | 0.00 | ||
| CashFlowFromContinuingFinancingActivities | -10.30B | -17.14B | 26.07B | -14.83B |
| NetOtherFinancingCharges | -459.00M | -469.00M | -632.00M | -335.00M |
| CashDividendsPaid | -9.77B | -9.51B | -9.25B | -8.98B |
| CommonStockDividendPaid | -9.77B | -9.51B | -9.25B | -8.98B |
| NetCommonStockIssuance | 0.00 | 0.00 | -2.00B | 0.00 |
| CommonStockPayments | 0.00 | 0.00 | -2.00B | 0.00 |
| NetIssuancePaymentsOfDebt | -74.00M | -7.16B | 35.95B | -3.52B |
| NetShortTermDebtIssuance | -3.00B | -4.91B | 7.68B | -218.00M |
| ShortTermDebtPayments | -3.00B | -13.82B | -3.00M | -4.11B |
| ShortTermDebtIssuance | 0.00 | 8.91B | 7.69B | 3.89B |
| NetLongTermDebtIssuance | 2.92B | -2.25B | 28.26B | -3.30B |
| LongTermDebtPayments | -6.76B | -2.25B | -2.57B | -3.30B |
| LongTermDebtIssuance | 9.68B | 0.00 | 30.83B | 0.00 |
| InvestingCashFlow | -1.35B | 2.65B | -32.28B | -15.78B |
| CashFromDiscontinuedInvestingActivities | 0.00 | 0.00 | -12.00M | |
| CashFlowFromContinuingInvestingActivities | -1.35B | 2.65B | -32.28B | -15.78B |
| NetOtherInvestingChanges | 165.00M | -180.00M | -192.00M | -306.00M |
| DividendsReceivedCFI | 0.00 | 0.00 | 3.96B | 0.00 |
| NetInvestmentPurchaseAndSale | 1.73B | -1.48B | 15.24B | 6.68B |
| SaleOfInvestment | 19.05B | 8.83B | 46.42B | 45.46B |
| PurchaseOfInvestment | -17.32B | -10.31B | -31.18B | -38.78B |
| NetBusinessPurchaseAndSale | -616.00M | 7.04B | -43.43B | -23.00B |
| SaleOfBusiness | 6.31B | 7.04B | 0.00 | 0.00 |
| PurchaseOfBusiness | -6.93B | 0.00 | -43.43B | -23.00B |
| NetPPEPurchaseAndSale | -2.63B | -2.91B | -3.91B | -3.24B |
| PurchaseOfPPE | -2.63B | -2.91B | -3.91B | -3.24B |
| OperatingCashFlow | 11.70B | 12.74B | 8.70B | 29.27B |
| CashFromDiscontinuedOperatingActivities | 0.00 | 0.00 | -343.00M | |
| CashFlowFromContinuingOperatingActivities | 11.71B | 12.74B | 8.70B | 29.27B |
| ChangeInWorkingCapital | -5.35B | -3.07B | -2.17B | -5.64B |
| ChangeInOtherWorkingCapital | -2.81B | -1.34B | -982.00M | -545.00M |
| ChangeInOtherCurrentLiabilities | -3.67B | -3.12B | 595.00M | -1.45B |
| ChangeInOtherCurrentAssets | 1.29B | 3.38B | -663.00M | -4.51B |
| ChangeInPayablesAndAccruedExpense | -469.00M | -1.02B | -300.00M | 1.19B |
| ChangeInPayable | -469.00M | -1.02B | -300.00M | 1.19B |
| ChangeInAccountPayable | -469.00M | -1.02B | -300.00M | 1.19B |
| ChangeInInventory | 561.00M | -854.00M | -1.17B | -591.00M |
| ChangeInReceivables | -263.00M | -109.00M | 347.00M | 261.00M |
| ChangesInAccountReceivables | -263.00M | -109.00M | 347.00M | 261.00M |
| OtherNonCashItems | -1.26B | -2.27B | -4.28B | -400.00M |
| StockBasedCompensation | 799.00M | 877.00M | 525.00M | 872.00M |
| AssetImpairmentCharge | 5.27B | 4.24B | 9.61B | 1.73B |
| DeferredTax | -2.13B | -2.10B | -3.44B | -3.76B |
| DeferredIncomeTax | -2.13B | -2.10B | -3.44B | -3.76B |
| DepreciationAmortizationDepletion | 6.59B | 7.01B | 6.29B | 5.06B |
| DepreciationAndAmortization | 6.59B | 7.01B | 6.29B | 5.06B |
| EarningsLossesFromEquityInvestments | 0.00 | |||
| NetIncomeFromContinuingOperations | 7.79B | 8.05B | 2.17B | 31.40B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PFE
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|